Two Novel Vitamin D Receptor Modulators with Similar Structures Exhibit Different Hypercalcemic Effects in 5/6 Nephrectomized Uremic Rats
Authors:
- J. Ruth Wu-WongJWJ. Ruth Wu-Wong
- Megumi KawaiMKMegumi Kawai
- Yung-Wu ChenYCYung-Wu Chen
- Jerry L. WessaleJWJerry L. Wessale
- Ching-Jang HuangCHChing-Jang Huang
- Meng-Ting WuMWMeng-Ting Wu
- Masaki NakaneMNMasaki Nakane
- 20 March 2013
- journal article
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 37 (4) , 310-319
Abstract
Background/Aims: Vitamin D receptor modulators (VDRMs) are indicated for secondary hyperparathyroidism in chronic kidney disease (CKD). Clinical observations demonstrate that VDRM therapy provides cardiovascular (CV) benefit in CKD. Current on-market VDRMs have a narrow therapeutic index at 1- to 4-fold [hypercalcemic toxicity vs. parathyroid hormone (PTH)-suppressing efficacy]. Hypercalcemia leads to the need for frequent drug dose titration and serum calcium (Ca) monitoring. A VDRM with a wider therapeutic index and beneficial CV effects will be clinically useful. Methods: Two structurally similar VDRMs were tested in the 5/6 nephrectomized (NX) rats with elevated PTH, endothelial dysfunction and left ventricular hypertrophy. Results: VS-110 and VS-411 at 0.01-1 μg/kg (i.p. 3 times/week for 2 weeks) suppressed serum PTH effectively. VS-411 raised serum Ca with an 11% increase at 0.01 μg/kg (therapeutic index = ∼1-fold), while VS-110 did not raise serum Ca even at 1 μg/kg (therapeutic index >50-fold). VS-110 improved endothelium-dependent aortic relaxation in a dose-dependent manner and significantly reduced left ventricular fibrosis without affecting serum Ca. VS-411 also exhibited effects on the CV parameters, but was less potent at the high doses with severe hypercalcemia. VS-110 and VS-411 specifically activated the reporter gene via a chimeric receptor containing the VDR ligand binding domain with EC50 <0.1 nM. Conclusions: Structurally similar VDRMs can exhibit distinctly different hypercalcemic effects in 5/6 NX uremic rats. While differences exist for the Ca and CV effects of VS-110 and VS-411, the clinical implications are unclear. VS-110's results are promising but clinical outcome studies need to be performed.Keywords
This publication has 52 references indexed in Scilit:
- Use of vitamin D in chronic kidney disease patientsKidney International, 2010
- Oral Paricalcitol in the Treatment of Patients With CKD and Proteinuria: A Randomized TrialAmerican Journal of Kidney Diseases, 2009
- Potential for vitamin D receptor agonists in the treatment of cardiovascular diseaseBritish Journal of Pharmacology, 2009
- Suppression of renin–angiotensin gene expression in the kidney by paricalcitolKidney International, 2008
- Paricalcitol Reduces Albuminuria and Inflammation in Chronic Kidney DiseaseHypertension, 2008
- Oral Calcitriol for the Treatment of Persistent Proteinuria in Immunoglobulin A Nephropathy: An Uncontrolled TrialAmerican Journal of Kidney Diseases, 2008
- Combination Therapy with an Angiotensin-Converting Enzyme Inhibitor and a Vitamin D Analog Suppresses the Progression of Renal Insufficiency in Uremic RatsJournal of the American Society of Nephrology, 2007
- Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney diseaseKidney International, 2007
- Antiproteinuric effect of oral paricalcitol in chronic kidney diseaseKidney International, 2005
- 22-Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized ratsNephrology Dialysis Transplantation, 2002